Zoetis Inc. (NYSE:ZTS) Shares Bought by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd raised its stake in Zoetis Inc. (NYSE:ZTS) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,217 shares of the company’s stock after purchasing an additional 251 shares during the period. Gulf International Bank UK Ltd’s holdings in Zoetis were worth $6,466,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ZTS. Norges Bank acquired a new stake in Zoetis in the 4th quarter valued at about $980,646,000. Price T Rowe Associates Inc. MD raised its position in Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Zoetis in the 4th quarter valued at about $242,757,000. CIBC Private Wealth Group LLC raised its position in Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock valued at $285,923,000 after purchasing an additional 797,884 shares in the last quarter. Finally, Corient Private Wealth LLC raised its position in Zoetis by 44.4% in the 4th quarter. Corient Private Wealth LLC now owns 1,953,508 shares of the company’s stock valued at $385,564,000 after purchasing an additional 600,804 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ZTS. The Goldman Sachs Group dropped their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus dropped their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Barclays dropped their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Finally, HSBC dropped their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $211.75.

Zoetis Trading Up 1.7 %

NYSE:ZTS opened at $171.09 on Friday. The stock’s 50 day moving average price is $166.56 and its 200 day moving average price is $179.20. The company has a market capitalization of $78.07 billion, a PE ratio of 32.97, a P/E/G ratio of 2.61 and a beta of 0.88. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.31 EPS. On average, research analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.01%. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.